Eupraxia's EP-104GI maintains clinical remission in 2/3 of patients at 12 months.

Eupraxia Pharmaceuticals has announced positive clinical data from its RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis. At 12 months, 2/3rds of patients remained in clinical remission. Patients have maintained clinically meaningful improvements in tissue health and no serious adverse events or oral or gastrointestinal candidiasis have been reported. The trial has followed patients up to 9 months and the company is encouraged by the results.

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has announced encouraging clinical data from its RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). The trial, which is a Phase 1b/2a, multicenter, open-label, dose-escalation study, has shown that at 12 months, 2/3rds of patients remained in clinical remission. The treatment, administered via 4 to 20 esophageal wall injections, has demonstrated clinically meaningful improvements in tissue health without any serious adverse events or oral or gastrointestinal candidiasis reported.

The RESOLVE trial has followed patients for up to 9 months, and the company is encouraged by the results. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically confirmed active EoE. The treatment has shown promising results in reducing symptoms and improving tissue health, which aligns with the company's proprietary Diffusphere™ technology platform designed to optimize local, controlled drug delivery.

Eupraxia plans to disclose additional data from the open-label Phase 1b/2a part of the RESOLVE trial in Q3 2025. The Phase 2b part of the RESOLVE trial, a randomized placebo-controlled study of EP-104GI, is currently recruiting and is expected to provide top-line data in Q3 2026.

EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview Healthcare Partners, EoE affects approximately 1 in 200 people and is often managed through daily oral steroids or weekly biologic injections, which can be inconvenient and have side effects.

The positive clinical data from the RESOLVE trial for EP-104GI highlights the potential of Eupraxia's Diffusphere™ technology platform to address high-unmet-need diseases. The company's growing string of positive clinical updates and unanimous Wall Street Buy ratings position it as a standout small-cap biotech with real near-term catalysts.

References:
[1] https://vistapglobal.com/eupraxia-pharmaceuticals-nasdaq-eprx-accelerates-toward-key-clinical-milestones-wall-street-remains-bullish/
[2] https://finance.yahoo.com/news/first-set-1-clinical-results-120000990.html